4.2(top 10%)
2-year impact
5.3(top 5%)
3-year impact
7.3(top 5%)
5-year impact
7.8(top 2%)
10-year impact
1.8K(top 10%)
PR articles
80.3K(top 5%)
PR citations
135(top 5%)
PR h-index
143(top 5%)
h-index
4.4(top 10%)
extended IF
4.0(top 10%)
2-YI (article-only)
10.8(top 20%)
2-YI (review-only)
3.5(top 20%)
2-YI (comm only)
4.2(top 10%)
2-YI (no self-cite.)
2.0K
documents
99.5K
doc citations

Top Articles

#TitleJournalYearCitations
1Myeloid-Derived Suppressor CellsCancer Immunology Research20171,393
2PD-L1 Expression in Triple-Negative Breast CancerCancer Immunology Research20141,031
3NF-κB, an Active Player in Human CancersCancer Immunology Research2014933
4Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene SignaturesCancer Immunology Research2019665
5Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid MalignanciesCancer Immunology Research2014656
6Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T CellsCancer Immunology Research2013644
7The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential SynergiesCancer Immunology Research2015626
8Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe ToxicityCancer Immunology Research2014516
9Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor AntigenCancer Immunology Research2015514
10An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung CancerCancer Immunology Research2013497
11In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human PrimatesCancer Immunology Research2014461
12T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in HumansCancer Immunology Research2013459
13NKG2D Receptor and Its Ligands in Host DefenseCancer Immunology Research2015457
14Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer TherapiesCancer Immunology Research2015456
15Bevacizumab plus Ipilimumab in Patients with Metastatic MelanomaCancer Immunology Research2014444
16T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B CellsCancer Immunology Research2016442
17Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLCCancer Immunology Research2017442
18Tumors: Wounds That Do Not Heal—ReduxCancer Immunology Research2015431
19Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic CellsCancer Immunology Research2015413
20The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor ActivityCancer Immunology Research2015410
21Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune RegulationCancer Immunology Research2014390
22Chemokines in CancerCancer Immunology Research2014366
23Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 BlockadeCancer Immunology Research2016364
24Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor CellsCancer Immunology Research2015359
25Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast CancerCancer Immunology Research2017355
26Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer PatientsCancer Immunology Research2017352
27IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory PhenotypeCancer Immunology Research2019345
28HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 BlockadeCancer Immunology Research2015341
29Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic CarcinomaCancer Immunology Research2015339
30The Immunological SynapseCancer Immunology Research2014335
31Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug DiscoveryCancer Immunology Research2017315
32Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 BlockadeCancer Immunology Research2014314
33Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal AntibodyCancer Immunology Research2015314
34Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory ReceptorsCancer Immunology Research2015314
35Exosomes Released from Tumor-Associated Macrophages Transfer miRNAs That Induce a Treg/Th17 Cell Imbalance in Epithelial Ovarian CancerCancer Immunology Research2018309
36PD-1 Blockade Expands Intratumoral Memory T CellsCancer Immunology Research2016304
37Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent ModelCancer Immunology Research2016304
38PD-1 Restrains Radiotherapy-Induced Abscopal EffectCancer Immunology Research2015303
39T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy SelectionCancer Immunology Research2018297
40PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast CancerCancer Immunology Research2015295
41Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint BlockadeCancer Immunology Research2017292
42Oncolytic Viruses and Their Application to Cancer ImmunotherapyCancer Immunology Research2014279
43Inflammasomes and CancerCancer Immunology Research2017278
44PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall SurvivalCancer Immunology Research2013276
45Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human TissuesCancer Immunology Research2015275
46Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple MyelomaCancer Immunology Research2019275
47Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCsCancer Immunology Research2018274
48PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8+ T Cells and Facilitates Anti–PD-1 TherapyCancer Immunology Research2018273
49Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and ActivationCancer Immunology Research2018269
50Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In VivoCancer Immunology Research2013268